Izinova (Magnesium Sulfate Heptahydrate, Sodium Sulfate Anhydrous, Potassium Sulphate)

The sulfates act as osmotic agents that draw water into the intestinal lumen, increasing stool bulk and promoting peristalsis. At the same time, the salts supply magnesium, sodium and potassium ions, supporting normal electrolyte concentrations in the body.

The appropriate dose of Izinova is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal function and electrolyte status. Patients should follow the specific instructions provided by their prescriber.

Safety of Izinova in pregnancy or while breastfeeding has not been fully established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare provider before using the product.

To order Izinova, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Izinova differs from many single‑ingredient laxatives by providing a combination of magnesium, sodium and potassium salts, which not only act as an osmotic laxative but also help replenish key electrolytes. This dual function can be advantageous for patients who need both bowel regulation and electrolyte support.

Izinova should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability and effectiveness.

Izinova is taken orally, usually with a full glass of water. The exact administration schedule, including timing relative to meals, should follow the prescribing clinician’s directions.

Serious risks include severe dehydration, hypermagnesemia, hyperkalemia and significant electrolyte imbalance, especially in patients with renal impairment or those taking interacting medications. Prompt medical attention is required if symptoms such as muscle weakness, irregular heartbeat or extreme thirst develop.

Izinova should be avoided in individuals with severe renal failure, complete bowel obstruction, known hypersensitivity to any of its components, or in patients taking medications that could cause dangerous electrolyte disturbances without close monitoring.